JPS6344724B2 - - Google Patents

Description

[Detailed description of the invention]

[Industrial Field of Application] The present invention relates to a therapeutic agent for athlete's foot (tinea hidridae), which is a type of skin disease, and in particular to an external drug thereof, and is utilized in the field of pharmaceutical formulations. [Prior Art] Athlete's foot is a skin disease in which Trichophyton grows in thick parts of the stratum corneum, such as the soles of the feet and the palms of the hands, causing lesions. Conventionally, there are many types of topical medications for athlete's foot on the market, but all of them have the effect of inhibiting the growth of tinea fungus in vitro, and there is not much difference in efficacy no matter which one is used. . However, athlete's foot is a skin disease that is difficult to cure completely, and even if it appears to have been cured, the bacteria often remains deep in the stratum corneum of the epidermis, and may grow again in the summer or when treated with medication. It often happens that athlete's foot grows again some time after you stop applying the product. The reason why athlete's foot is difficult to cure is that the fungus is parasitic in the stratum corneum, which is difficult for drugs to penetrate, and that it is often caused by a species of Trichophyton that is relatively resistant to drugs. by. For this reason, laboratory drug effects often do not directly translate into clinical therapeutic effects, and athlete's foot is generally considered to be one of the skin diseases that is difficult to completely cure.
The treatment method is to prove the type of Trichophyton that is the cause and select the most effective drug for that type of bacteria.
It is best to continue applying it patiently, keep your hands and feet clean, and keep the areas between your fingers dry. [Problems to be solved by the invention] Conventional drugs for treating athlete's foot may have little or no efficacy depending on the type of ringworm fungus, or may show remarkable efficacy in laboratory tests, but may not actually affect the human body. When administered, the therapeutic effect may not be as great. Even if the disease appears to have been cured, recurrence often occurs at a later date, and cure requires great patience on the part of the patient over a long period of time. This invention solves all of the above-mentioned problems that were unsatisfactory with conventional treatments for athlete's foot, achieves extremely good clinical therapeutic effects in a short period of time, regardless of bacterial species, and prevents recurrence at a later date. This was done in order to provide an external medicine for athlete's foot that can completely cure athlete's foot without any complications. [Means for Solving the Problems] As a technical means for solving the above problems, this invention uses at least one type of antifungal agent, 2, 4,
A topical medicine for athlete's foot was prepared by mixing 4'-trichloro-2'-hydroxy diphenyl ether and urea, a keratin softener, into a hydrophilic ointment base or an aqueous ethanol solution. Here, 2,4,4'-trichloro-2'-hydroxy diphenyl ether is an antibacterial agent developed by Ciba Geigy of Switzerland (trade name:
Irgasan DP300) is a drug that has no practical toxicity and does not cause skin irritation or sensitization in skin toxicity tests.It is highly compatible with the skin and is mainly used as a disinfectant for hands and fingers. . (Pharmaceutical Journal, March 1975 issue, pages 163-166, Nippon Medical Newspaper
No. 2630, P48-51, etc.) The content of this 2,4,4'-trichloro-2'-hydroxy diphenyl ether in the above external medicine for athlete's foot is 0.2-2.0% by weight (or 0.2-2.0W/V %), particularly about 1.0% by weight (or 1.0W/V%). Next, urea is a safe keratin softener with extremely low toxicity, and its content in the above external medicine for athlete's foot is 5 to 5.
40% by weight (or 5-40W/V%), especially 10
It is about % by weight (or 10W/V%). [Function] In the topical medicine for athlete's foot according to the present invention, urea, which is one of its constituent ingredients, increases the water retention capacity of the skin and swells and softens the stratum corneum, helping the drug to penetrate deep into the stratum corneum. It dissolves and exfoliates the stratum corneum, reduces the thickness of the stratum corneum itself, increases transdermal absorption of drugs, and uses an antifungal agent to kill Trichophyton parasitizing the stratum corneum. 2, which has a broad antifungal spectrum and has excellent antifungal effects.
4,4'-trichloro-2'-hydroxy diphenyl ether completely kills various and highly resistant bacterial species. [Example] Examples of the present invention and the results of comparative tests conducted regarding the antifungal performance of the external medicine for athlete's foot according to the examples will be described below. First, a method for determining the effectiveness rate (antifungal spectrum) and average effective inhibition index (antifungal activity) of a drug against various fungi will be explained with reference to FIGS. 1 and 2. First, agar is spread inside the shear dish 1, used as a fungal medium 2, and fungi are evenly inoculated. Next, a paper 3 having a diameter of 6 mm is impregnated with a certain amount of the drug, dried, and placed on the surface of the fungal medium 2. As a result, the drug impregnated into the paper 3 is diffused into the agar, and if the drug has a growth inhibiting effect on the fungal species, the paper 3 and the fungal growth area A If no fungus grows between the two, an inhibition zone B is formed. This blocking ring B
Measure the width t of , and determine the effective unit for each case based on Table 1.

[Table] Then, the effectiveness rate and average effective inhibition index of each drug are calculated using the following formula.

[Table] _i=0
=

Claims (1)

[Claims] 1 0.2 to 2.0% by weight of 2,4,4'-trichloro-
A topical medicine for athlete's foot prepared by mixing 2'-hydroxy diphenyl ether and 5 to 40% by weight of urea in a hydrophilic ointment base or an ethanol aqueous solution. 2. The external medicine for athlete's foot according to claim 1, which contains 1.0% by weight of 2,4,4'-trichloro-2'-hydroxy diphenyl ether and 10% by weight of urea. 3 0.2-2.0 W/V% of 2,4,4'-trichloro-2'-hydroxy diphenyl ether and 5-
The external medicine for athlete's foot according to claim 1, which is obtained by dissolving 40 W/V% of urea in a 50% aqueous ethanol solution. 4 1.0W/V% 2,4,4'-trichloro-2'-
The external medicine for athlete's foot according to claim 3, which contains hydroxy diphenyl ether and 10 W/V% urea. 5. The external medicine for athlete's foot according to any one of claims 1 to 4, which contains a small amount of sulfuric acid as a stabilizer.